Pier 88 Investment Partners LLC Sells 5,710 Shares of Insulet Corporation $PODD

Pier 88 Investment Partners LLC trimmed its stake in Insulet Corporation (NASDAQ:PODD) by 86.4% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 900 shares of the medical instruments supplier’s stock after selling 5,710 shares during the period. Pier 88 Investment Partners LLC’s holdings in Insulet were worth $256,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in PODD. Whittier Trust Co. of Nevada Inc. raised its stake in shares of Insulet by 48.9% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 131 shares of the medical instruments supplier’s stock valued at $40,000 after acquiring an additional 43 shares in the last quarter. Quent Capital LLC bought a new position in shares of Insulet in the 3rd quarter valued at approximately $49,000. Measured Wealth Private Client Group LLC acquired a new stake in Insulet in the 3rd quarter valued at approximately $49,000. Osterweis Capital Management Inc. acquired a new stake in Insulet in the 2nd quarter valued at approximately $51,000. Finally, Zions Bancorporation National Association UT grew its holdings in Insulet by 57.3% in the 3rd quarter. Zions Bancorporation National Association UT now owns 173 shares of the medical instruments supplier’s stock valued at $53,000 after buying an additional 63 shares during the last quarter.

Insider Buying and Selling at Insulet

In other news, Director Michael R. Minogue acquired 2,030 shares of the firm’s stock in a transaction dated Wednesday, February 25th. The shares were bought at an average price of $246.23 per share, with a total value of $499,846.90. Following the acquisition, the director owned 17,483 shares of the company’s stock, valued at $4,304,839.09. This trade represents a 13.14% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.36% of the company’s stock.

Wall Street Analyst Weigh In

PODD has been the topic of a number of research analyst reports. Jefferies Financial Group lowered their target price on Insulet from $400.00 to $360.00 in a report on Thursday, May 7th. Weiss Ratings raised Insulet from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, May 1st. Sanford C. Bernstein lowered their target price on Insulet from $330.00 to $200.00 and set an “outperform” rating on the stock in a report on Thursday. Citigroup lowered their target price on Insulet from $230.00 to $175.00 in a report on Thursday, May 7th. Finally, Wells Fargo & Company lowered their target price on Insulet from $360.00 to $255.00 and set an “overweight” rating on the stock in a report on Wednesday, May 6th. Eighteen equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $257.09.

Key Headlines Impacting Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet was highlighted by Zacks as a top value stock for the long term, suggesting some investors still see attractive upside despite the recent pullback. Why Insulet (PODD) is a Top Value Stock for the Long-Term
• Positive Sentiment: The company announced a Middle East regional headquarters in Riyadh, a strategic expansion that could support international growth over time. Insulet establishes Middle East regional headquarters in Riyadh, marking a strategic milestone in the Kingdom
• Neutral Sentiment: Short interest data showed no meaningful change, with reported short interest at 0 shares, so this does not appear to be a driver of the stock move.
• Negative Sentiment: Several analysts lowered price targets for Insulet, including Jefferies, Citi, Stifel, Canaccord, Leerink, Raymond James, Baird, Oppenheimer, and Evercore, signaling softer near-term expectations and pressuring the stock. Jefferies Financial Group Cuts Insulet (NASDAQ:PODD) Price Target to $360.00

Insulet Price Performance

Shares of NASDAQ:PODD opened at $154.17 on Tuesday. Insulet Corporation has a 1-year low of $148.30 and a 1-year high of $354.88. The firm has a market capitalization of $10.68 billion, a PE ratio of 35.85, a PEG ratio of 1.25 and a beta of 1.20. The business’s 50 day moving average is $207.40 and its 200-day moving average is $261.40. The company has a current ratio of 2.49, a quick ratio of 1.81 and a debt-to-equity ratio of 0.71.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, topping the consensus estimate of $1.19 by $0.23. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The company had revenue of $761.70 million for the quarter, compared to analyst estimates of $729.89 million. During the same quarter last year, the firm earned $1.02 EPS. Insulet’s revenue for the quarter was up 33.9% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.210- EPS. Sell-side analysts predict that Insulet Corporation will post 6.43 earnings per share for the current year.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.